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Phage lytic enzymes are enzymes produced by bacterial viruses, either as part of their virion
to facilitate bacterial infection through local peptidoglycan degradation, or as soluble proteins to
induce massive cell lysis at the end of the lytic replication cycle. In a pioneering paper from
the Fischetti laboratory, the in vivo efficacy of streptococcal phage C1 lysin was demonstrated
against group A streptococci in a mouse respiratory model [1]. In the following years, the field
of phage lytic enzymes has drastically expanded, first for Gram-positive pathogens, and later also
for Gram-negative pathogens through protein engineering [2,3]. Many new phage lytic enzymes
active against diverse pathogens have been discovered and characterized. Their in vitro and in vivo
properties as anti-infectives have been reported for an increasing number of applications or clinical
indications. I am pleased to have witnessed the growing community of researchers focusing on phage
lytic proteins during the last decade. In this issue, Vincent Fischetti provides an historical and personal
perspective on the development of phage lytic enzymes as antimicrobials in his laboratory preceding
this global attention for phage lytic enzymes [4].
From the growing body of preclinical evidence, phage lytic enzymes are now generally considered
as a novel class of antimicrobials with great potential. Their rapid action, strong bactericidal effect, lack
of resistance development and activity against persister cells are all related with their unique mode
of action. Eighteen years after the first published in vivo efficacy tests, this special issue coincides
with the first ongoing clinical phase II trials. The clinical evaluation of phage lytic enzymes has now
caught up with the clinical evaluation of their parental producers; i.e., bacteriophages. The latter have
been considered as antimicrobials since their discovery at the beginning of the 20th century, but were
confronted with several technical and regulatory hurdles. Both phages and phage lytic enzymes
represent novel classes of antimicrobials that are differentiated from the traditional small molecule
antibiotics, responding to the urgent call of novel antibiotics [5].
This special issue provides an excellent review on the basic biology of phage lytic enzymes during
both infection and lysis [6]. This review goes hand in hand with a review from the Azeredo group
that focuses on the challenges and future prospects for in vivo therapy [7]. The authors emphasize the
difficulties of translating the in vitro performance of phage lytic enzymes to in vivo efficacy and give
recommendations to increase the success rate. One of them is the engineering of phage lytic enzymes
by domain swapping. Two applications of a chimeric lysin, specifically ClyR which has extended
antistreptococcal activity, have been reported in this special issue. Xu and colleagues demonstrated
the anticaries efficacy of ClyR in a rat model [8], while Li and colleagues report the efficacy of ClyR
against planktonic and sessile Enterococcus faecalis in an ex vivo dental model [9]. The antibiofilm
activity appears to be again essential for success. From this perspective, the synergy between a
depolymerase degrading extracellular polysaccharides and an endolysin has been studied in both
static and dynamic biofilm models [10]. When bringing phage lytic enzymes closer to applications,
formulation will be increasingly important. In this issue, the formulation of an anti-Staphylococcus
aureus endolysin has been reported in an Aquaphor-based ointment along with the peptide apigenin
for its anti-inflammatory and anti-haemolysis activity [11].
The discovery of new phage lytic enzymes remains essential to exploiting the best of the large
natural diversity. Four new endolysins are reported and described in this special issue. Three Bacillus
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phage endolysins with broad antimicrobial activity against Bacillus cereus sensu lato strains were
identified and characterized [12]. Melo and colleagues isolated an endolysin from a new S. aureus
phage with antibiofilm activity [13]. Many S. aureus endolysins, including the one described by Melo
in this issue, have a central amidase domain for which the function is still unknown. An auxiliary role
of this amidase domain in the binding affinity of the cell wall binding domain is proposed, resulting in
increased antimicrobial activity [14].
The majority of reports in this special issue are focused on phage lytic enzymes targeting
Gram-positive pathogens, whereas the need for novel alternatives to treat Gram-negative infections
is clinically the most pressing. The recurrent challenge in the design of phage lytic enzymes
targeting Gram-negative pathogens is the outer membrane, requiring engineering or intrinsic outer
membrane-permeabilizing activity. The study of Sykilinda and colleagues contributes to this field [15].
They present the three-dimensional structure of AcLys. The enzyme is featured by a highly charged
C-terminal α-helix. This peptide is presumed to interact with and transiently permeabilize the
outer membrane. Mycobacterium represents another group of bacteria with an urgent necessity for
novel therapeutics, but which remains challenging for phage lytic enzymes because of the unusual
outer membrane structure based on mycolic acids. Despite the large number of known phage lytic
enzymes described in Mycobacteria phages [16], their complicated cell wall structure requires more
extensive research to be overcome by phage lytic enzymes. In this issue, the current knowledge on
Mycobacterium phages and their phage lytic enzymes, focused on the model endolysin from phage
Ms2, and their applications as anti-infectives, has been reviewed [17].
Phage lytic enzymes should not only be considered for applications in health care. For virtually
any situation in which bacteria are harmful, it becomes relevant to study phage lytic enzymes as a
potential solution. For example, the bacterial contamination of yeast fermentations may decrease the
yield and thus the revenues. The use of a yeast strain either producing intracellularly or secreting
a lytic protein was studied to protect bioethanol fermentations from contamination with lactic acid
bacteria, resulting in improved bioethanol productivity [18].
We hope the research articles and reviews of this special issue will provide further inspiration
to expand phage lytic enzymes as a broad class of promising anti-infectives. While many beneficial
properties of those lytic enzymes are broadly shared, the number of applications is legio. We wish
to encourage all readers to continue the in-depth research of phage lytic enzymes, to initiate new
applications and to further fill the clinical development pipeline.
References
1. Nelson, D.; Loomis, L.; Fischetti, V.A. Prevention and elimination of upper respiratory colonization of mice
by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 2001, 98, 4107.
[CrossRef] [PubMed]
2. Gerstmans, H.; Criel, B.; Briers, Y. Synthetic biology of modular endolysins. Biotechnol. Adv. 2018, 36, 624.
[CrossRef] [PubMed]
3. Briers, Y.; Walmagh, M.; van Puyenbroeck, V.; Cornelissen, A.; Cenens, W.; Aertsen, A.; Oliveira, H.;
Azeredo, J.; Verween, G.; Pirnay, J.P.; et al. Engineered endolysin-based “Artilysins” to combat
multidrug-resistant gram-negative pathogens. MBio 2014, 5, e01379-14. [CrossRef] [PubMed]
4. Fischetti, V.A. Development of phage lysins as novel therapeutics: a historical perspective. Viruses 2018, 10,
310. [CrossRef] [PubMed]
5. Abdelkader, K.; Gerstmans, H.; Saafan, A.; Dishisha, T.; Briers, Y. The preclinical and clinical progress of
bacteriophages and their lytic enzymes: The parts are easier of the whole. Viruses 2019, 11, 96. [CrossRef]
[PubMed]
6. Fernandes, S.; São-José, C. Enzymes and mechanisms employed by tailed bacteriophages to breach the
bacterial cell barriers. Viruses 2018, 10, 396. [CrossRef] [PubMed]
7. Oliveira, H.; São-José, C.; Azeredo, J. Phage-derived peptidoglycan degrading enzymes: challenges and
future prospects for in vivo therapy. Viruses 2018, 10, 292. [CrossRef] [PubMed]
Viruses 2019, 11, 113 3 of 3
8. Xu, J.; Yang, H.; Bi, Y.; Li, W.; Wei, H.; Li, Y. Activity of the chimeric lysin ClyR against common Gram-positive
oral microbes and its anticaries efficacy in rat models. Viruses 2018, 10, 380. [CrossRef] [PubMed]
9. Li, W.; Yang, H.; Gong, Y.; Wang, S.; Li, Y.; Wei, H. Effects of a chimeric lysin against planktonic and sessile
Enterococcus faecalis hint at potential application in endodontic therapy. Viruses 2018, 10, 290. [CrossRef]
[PubMed]
10. Olsen, N.M.C.; Thiran, E.; Hasler, T.; Vanzieleghem, T.; Belibasakis, G.S.; Mahillon, J.; Loessner, M.J.;
Schmelcher, M. Synergistic removal of static and dynamic Staphylococcus aureus biofilms by combined
treatment with a bacteriophage endolysin and a polysaccharide depolymerase. Viruses 2018, 10, 438.
[CrossRef] [PubMed]
11. Cheng, M.; Zhang, L.; Zhang, H.; Li, X.; Wang, Y.; Xia, F.; Wang, B.; Cai, R.; Guo, Z.; Zhang, Y.; et al. An
ointment consisting of the phage lysin LysGH15 and apigenin for decolonization of methicillin-resistant
Staphylococcus aureus from skin wounds. Viruses 2018, 10, 244. [CrossRef] [PubMed]
12. Etobayeva, I.; Linden, S.B.; Alem, F.; Harb, L.; Rizkalla, L.; Mosier, P.D.; Johnson, A.A.; Temple, L.;
Hakami, R.M.; Nelson, D.C. Discovery and biochemical characterization of PlyP56, PlyN74, and
PlyTB40—Bacillus specific endolysins. Viruses 2018, 10, 276. [CrossRef] [PubMed]
13. Melo, L.D.R.; Brandão, A.; Akturk, E.; Santos, S.B.; Azeredo, J. Characterization of a new Staphylococcus
aureus Kayvirus harboring a lysin active against biofilms. Viruses 2018, 10, 182.
14. Son, B.; Kong, M.; Ryu, S. The auxiliary role of the amidase domain in cell wall binding and exolytic activity
of staphylococcal phage endolysins. Viruses 2018, 10, 284. [CrossRef] [PubMed]
15. Sykilinda, N.N.; Nikolaeva, A.Y.; Shneider, M.M.; Mishkin, D.V.; Patutin, A.A.; Popov, V.O.; Boyko, K.M.;
Klyachko, N.L.; Miroshnikov, K.A. Structure of an Acinetobacter broad-range prophage endolysin reveals
a C-Terminal α-helix with the proposed role in activity against live bacterial cells. Viruses 2018, 10, 309.
[CrossRef] [PubMed]
16. Payne, K.M.; Hatfull, G.F. Mycobacteriophage endolysins: diverse and modular enzymes with multiple
catalytic activities. PLoS ONE 2012, 7, e34052. [CrossRef] [PubMed]
17. Catalão, M.J.; Pimentel, M. Mycobacteriophage lysis enzymes: targeting the mycobacterial cell envelope.
Viruses 2018, 10, 428.
18. Kim, J.-S.; Daum, M.A.; Jin, Y.-S.; Miller, M.J. Yeast-derived LysA2 can control bacterial contamination in
ethanol fermentation. Viruses 2018, 10, 281. [CrossRef] [PubMed]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
